Identifying Novel Targets, Navigating the Alpha vs Beta Debate & Optimizing Targeting Moieties, Linkers, Chelators, & Drug Design Strategies to Build the Next Generation of Targeted Radiopharmaceuticals
Targeted radiopharmaceuticals are entering a new phase of competition and innovation. With 298 programs now in preclinical development, pipelines are expanding rapidly, yet activity remains concentrated around a relatively small number of established targets.
As more programs compete for differentiation, the 3rd TRP Target Selection & Drug Design Summit (February 23–25 | Boston) is the only industry-focused meeting purpose-built for drug-developers to understand which targets, isotopes and drug design strategies will define the next generation of clinically and commercially successful radiopharmaceuticals.
Join 100+ scientific, technical and strategic leaders across biotech, pharma, regulations and academia to tackle the scientific and strategic challenges underpinning radiopharmaceutical target selection and drug design.
Your Dose of TRP Target Selection & Drug Design
With expertise from AstraZeneca, Bayer, Pfizer, Molecular Partners, Affibody, Ratio Therapeutics, Matrisome Bio, Harvard Medical School, University of Pennsylvania, ex-FDA and more.
If you're working to push a candidate towards the clinic, expand your target landscape, mine other modalities for clinically validated targets, select the right radionuclide, optimize your drug design or strengthen your preclinical package, this is the room to be in.
Join the industry's only meeting dedicated exclusively to the earliest and most consequential stages of RLT development, and benchmark the science and strategy that will define the next generation of differentiated radiopharmaceuticals.
While everyone came with a different perspective, there was a real sense that everyone was prepared to discuss the key issues facing our field in a productive manner.
Past Attendee, Director, AstraZeneca
I liked the balance of having both preclinical and clinical speakers that could give an overall picture of the challenges that come with RLTs.
Past Attendee, Senior Scientific Lead, ADME & DMPK, Eli Lilly
From my point of view speakers and companies attending the conference were very well picked. Also, the scope of the conference with a rather selected number of attendants generated a nice, familiar atmosphere. It gave a good possibility to connect with people in the field. Also, the talks were nicely picked and aligned in the conference program.
Past Attendee, Director, Program Management, PentixaPharm
Explore the Full Event Guide
- 100+ RLT Experts across discovery, preclinical development, drug design, imaging, dosimetry & safety
- 20+ Expert Speakers from leading pharma, biotech, academia & regulatory
- 2 Brand-New Interactive Workshops tackling cross-modality target mining & kinetic imaging for target validation
- 20+ Hours of Structured Networking to build and foster connections from the very first day
- Brand New FDA regulatory insights from former EX-FDA specialist
- The Industry’s Only Forum Dedicated Exclusively to RLT Target Selection & Drug Design
Attending Companies Include
2027 Partners
Explore Related Events
Explore the Agenda
Discover the target selection, drug design and preclinical strategies to identify differentiated targets, optimize next-generation radiopharmaceuticals and build the evidence needed to progress towards the clinic.
Partner With Us
Position your expertise in front of 100+ discovery and preclinical RLT leaders actively seeking technologies, services and specialist partners across target discovery, drug design, imaging, radiochemistry, preclinical development, dosimetry, and safety.
Join RLT Experts
Join 100+ radiochemists, biologists, drug designers, and R&D leaders advancing next-generation radioligand therapies from discovery through translation.